Fig. 4From: Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosisIndividual changes in body mass index following Elexacaftor/Tezacaftor/Ivacaftor therapy in patients with cystic fibrosis who were underweight at baseline visit (panel a) and among patients who became overweight during the study period (panel b)Back to article page